Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa‐2b in HBeAg‐positive patients (Q51754356)

From Wikidata

Jump to navigation Jump to search

scientific article published on September 1, 2010

Language	Label	Description	Also known as
English	Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa‐2b in HBeAg‐positive patients	scientific article published on September 1, 2010

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/20796146

Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa‐2b in HBeAg‐positive patients (English)

reason for preferred rank

most precise value

1 reference

10.1111/J.1440-1746.2010.06282.X

https://api.crossref.org/works/10.1111/J.1440-1746.2010.06282.X

2 July 2024

Quantitative serum HBsAg and HBeAg are strong predictors of sustained HBeAg seroconversion to pegylated interferon alfa-2b in HBeAg-positive patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20796146

2 July 2024

1 reference

based on heuristic

inferred from title

pegylated interferon

1 reference

based on heuristic

inferred from title

author name string

Hui Ma

1

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/20796146

Rui-Feng Yang

2

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/20796146

Lai Wei

3

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/20796146

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20796146

2 July 2024

publication date

1 September 2010

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/20796146

full work available at URL

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1440-1746.2010.06282.x

1 reference

10.1111/J.1440-1746.2010.06282.X

https://api.crossref.org/works/10.1111/J.1440-1746.2010.06282.X

2 July 2024

https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1440-1746.2010.06282.x

1 reference

10.1111/J.1440-1746.2010.06282.X

https://api.crossref.org/works/10.1111/J.1440-1746.2010.06282.X

2 July 2024

Journal of Gastroenterology and Hepatology

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/20796146

25

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/20796146

9

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/20796146

1498-1506

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/20796146

Chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2010.06282.X

21 January 2018

Hepatitis B virus infection--natural history and clinical consequences

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2010.06282.X

21 January 2018

Management of hepatitis B: summary of a clinical research workshop

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2010.06282.X

21 January 2018

Prevention and surveillance of hepatitis B virus-related hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2010.06282.X

21 January 2018

Antiviral actions of interferons

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2010.06282.X

21 January 2018

The virus battles: IFN induction of the antiviral state and mechanisms of viral evasion

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2010.06282.X

21 January 2018

Interferons alpha and beta as immune regulators--a new look

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2010.06282.X

21 January 2018

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2010.06282.X

21 January 2018

HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2010.06282.X

21 January 2018

Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2010.06282.X

21 January 2018

Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2010.06282.X

21 January 2018

Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2010.06282.X

21 January 2018

High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2010.06282.X

21 January 2018

Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2010.06282.X

21 January 2018

A controlled trial of interferon with or without prednisone priming for chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2010.06282.X

21 January 2018

How does interferon exert its cell growth inhibitory effect?

8

1 reference

10.1111/J.1440-1746.2010.06282.X

https://api.crossref.org/works/10.1111/J.1440-1746.2010.06282.X

2 July 2024

A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group

10

1 reference

10.1111/J.1440-1746.2010.06282.X

https://api.crossref.org/works/10.1111/J.1440-1746.2010.06282.X

2 July 2024

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

14

1 reference

10.1111/J.1440-1746.2010.06282.X

https://api.crossref.org/works/10.1111/J.1440-1746.2010.06282.X

2 July 2024

Identifiers

10.1111/J.1440-1746.2010.06282.X

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/20796146

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 April 2018

http://europepmc.org/abstract/MED/20796146

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51754356&oldid=2193675065"